Lenalidomide versus bortezomib maintenance after autologous stem cell transplantation in patients with high-risk multiple myeloma and chronic kidney disease
Lenalidomide versus bortezomib maintenance after autologous stem cell transplantation in patients with high-risk multiple myeloma and chronic kidney disease. // Current Problems in Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S0147027226000851?dgcid=rss_sd_all
Lenalidomide versus bortezomib maintenance after autologous stem cell transplantation in patients with high-risk multiple myeloma and chronic kidney disease. Current Problems in Cancer. https://www.sciencedirect.com/science/article/pii/S0147027226000851?dgcid=rss_sd_all
“Lenalidomide versus bortezomib maintenance after autologous stem cell transplantation in patients with high-risk multiple myeloma and chronic kidney disease.” Current Problems in Cancer.
@article{article107370,
title = {Lenalidomide versus bortezomib maintenance after autologous stem cell transplantation in patients with high-risk multiple myeloma and chronic kidney disease},
journal = {Current Problems in Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S0147027226000851?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment